GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hwail Pharm Co Ltd (XKRX:061250) » Definitions » EV-to-EBITDA

Hwail Pharm Co (XKRX:061250) EV-to-EBITDA : 9.74 (As of May. 12, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Hwail Pharm Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hwail Pharm Co's enterprise value is ₩51,842 Mil. Hwail Pharm Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₩5,321 Mil. Therefore, Hwail Pharm Co's EV-to-EBITDA for today is 9.74.

The historical rank and industry rank for Hwail Pharm Co's EV-to-EBITDA or its related term are showing as below:

XKRX:061250' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.64   Med: 13.69   Max: 124.56
Current: 9.74

During the past 13 years, the highest EV-to-EBITDA of Hwail Pharm Co was 124.56. The lowest was -13.64. And the median was 13.69.

XKRX:061250's EV-to-EBITDA is ranked better than
67.66% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.76 vs XKRX:061250: 9.74

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Hwail Pharm Co's stock price is ₩1628.00. Hwail Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩59.000. Therefore, Hwail Pharm Co's PE Ratio for today is 27.59.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Hwail Pharm Co EV-to-EBITDA Historical Data

The historical data trend for Hwail Pharm Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hwail Pharm Co EV-to-EBITDA Chart

Hwail Pharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.65 32.02 13.41 -18.37 11.85

Hwail Pharm Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.37 -9.38 -7.68 69.25 11.85

Competitive Comparison of Hwail Pharm Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Hwail Pharm Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hwail Pharm Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hwail Pharm Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hwail Pharm Co's EV-to-EBITDA falls into.



Hwail Pharm Co EV-to-EBITDA Calculation

Hwail Pharm Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=51842.270/5321.335
=9.74

Hwail Pharm Co's current Enterprise Value is ₩51,842 Mil.
Hwail Pharm Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩5,321 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hwail Pharm Co  (XKRX:061250) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Hwail Pharm Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1628.00/59.000
=27.59

Hwail Pharm Co's share price for today is ₩1628.00.
Hwail Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩59.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Hwail Pharm Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Hwail Pharm Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Hwail Pharm Co (XKRX:061250) Business Description

Traded in Other Exchanges
N/A
Address
904-7, Sangsin-Ri, Hyangnam-Eup, Hwaseong, Gyeonggi, KOR, 445-746
Hwail Pharm Co Ltd is engaged in manufacturing and distribution of raw materials used in pharmaceutical production. Its products include antitussive expectorants, spasmolytic, stomach function modifier, anti-inflammatory, and others.

Hwail Pharm Co (XKRX:061250) Headlines

No Headlines